BANGLADESH EXPORT IMPORT COMPANY LIMITED AND ITS SUBSIDIARIES

as at 31 December 2011

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

NOTES

AMOUNT INTAKA
31-Dec-11

31Dec-10

29,779,687,183
26,533,072,120
2,416,476,475
12,246,845
817,891,743
45,339,106,305

7,909,782,922
4,504,114,739
3,040,798,689
24,493,691
340,375,803
22,659,992,465

ASSETS
Non - Current Assets
Property, Plant and Equipment
Investment In Shares
Deferred Assets
Capital Work in Progress
Current Assets
Inventories
Debtors
Advances, Deposits and Pre-Payments
Cash and Cash Equivalents
Total Assets

5,787,165,141
22,301,349,217
16,991,382,503
259,209,444
75,118,793,488

4,406,964,821
11,686,784,943
6,269,158,960
297,083,741
30,569,775,387

SHAREHOLDERS EQUITY, NON-CONTROLLING INTEREST AND LIABILITIES

Shareholders Equity

44,079,962,117

17,843,954,106

Issued Share Capital

3,535,208,570
Reserve
23,625,786,188
Retained Earnings
16,918,967,359
Non-Controlling (Minority) Interest In Subsidiaries 1,350,281,988
Long Term Loan
5,220,136,740
Deferred Tax Liability
9,965,449

1,654,795,800
5,662,834,348
10,526,323,958
1,246,083,596
1,078,512,573
13,892,058

Current Liabilities
Short Term Loan From Banks and others
Long Term Loan - Current Portion
Trade and other Payables
Income Tax Payable
Total Equity and Liabilities

24,458,447,194
7,379,102,594
3,424,619,599
12,588,303,879
1,066,421,122
75,118,793,488

10,387,333,054
1,931,589,855
879,519,277
7,149,621,863
426,602,059
30,569,775,387

NOTES

AMOUNT INTAKA
31-Dec-11

Revenue (Turnover) from net Sales

Cost of Goods Sold

29,339,932,714
(16,260,877,280)

Gross Operating Profit

Operating Expenses

13,079,055,434
(1,450,826,746)

31Dec-10
18,980,964,619
(10,715,521,890)
8,265,442,729
(253,072,253)

Administrative Expenses
Selling and Distribution Expenses
Exchange Loss (10,120,204) Operating Profit
Financial Expenses

(1,365,536,627)
(75,169,915)

(177,621,212)
(75,451,041)

11,628,228,688
(3,219,854,322)

8,012,370,476
(633,592,074)

Net Profit before Cont. to WPWF

Net Profit Before Income Tax
Income Tax Expenses
Net Profit after Tax
Non-Controlling (Minority) Interest in Income

8,408,374,366
(400,398,779)
8,007,975,587
(674,985,413)
7,332,990,174
(84,384,072)

7,378,778,402
(15,253,704)
7,363,524,698
(379,328,727)
6,984,195,971
(126,623,714)

Net Profit after Non-Controlling (Minority) Interest

7,248,606,102

6,857,572,257

Contribution to Workers Profit Participation / Welfare Fund

Other Comprehensive Income

Revaluation Surplus on Property, Plant & Equipments
Fair Value Gain on Investment in Shares

7,601,395,496
86,202,955

Total Comprehensive Income after minority interest 14,936,204,553

EPS (Par Value of Share Tk. 10/=) (Adjusted EPS of 2010) 20.50

------------------6,857,572,257
19.40

BEXIMCO PHARMACEUTICALS LIMITED

Balance Sheet
As at 31 December 2009

NOTES

AMOUNT INTAKA
31-Dec-09

ASSETS
Non-Current Assets
Property, Plant and Equipment- Carrying Value
Intangible Assets
Investment in Shares
Current Assets
Inventories
Spares & Supplies
Accounts Receivable
Loans, Advances and Deposits
Short Term Investment
Cash and Cash Equivalents
TOTAL ASSETS

12,975,195,529
12,966,587,178
5,726,525
2,881,826
6,916,737,893
1,722,953,284
242,034,855
94,111,730
699,204,450
2,500,000,000
1,058,433,574
19,891,933,422

SHAREHOLDERS' EQUITY AND LIABILITIES

Shareholders' Equity
Issued Share Capital
Share Premium
Excess of Issue Price over Face Value of GDRs
Capital Reserve on Merger
Revaluation Surplus
Retained Earnings
Non-Current Liabilities
Long Term Borrowings-Net off Current Maturity (Secured)
Fully Convertible, 5% Dividend, Preference Share
Liability for Gratuity & WPPF
Deferred Tax Liability
Current Liabilities and Provisions
Short Term Borrowings
Long Term Borrowings-Current Maturity
Creditors and Other Payables
Accrued Expenses
Dividend Payable
Income Tax Payable
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

10,885,706,614
1,511,492,960
1,489,750,000
1,689,636,958
294,950,950
1,617,361,714
4,282,514,032
6,684,775,166
1,924,933,065
4,100,000,000
307,425,614
352,416,487
2,321,451,642
1,451,326,354
308,820,056
409,898,122
79,094,905
1,727,724
70,584,481
19,891,933,422

BEXIMCO PHARMACEUTICALS LIMITED

Profit and Loss Account

For the year ended 31 December 2009

NOTES

AMOUNT INTAKA
31-Dec-09

Net Sales Revenue

Cost of Goods Sold
Gross Profit
Operating Expenses :
Administrative Expenses
Selling, Marketing and Distribution Expenses
Profit from Operations
Other Income
Finance Cost
Profit Before Contribution to WPPF
Contribution to Workers' Profit Participation/ Welfare Funds
Profit Before Tax
Income Tax Expense
Current Tax Deferred Tax (Expense) / Income
Profit After Tax Transferred to Statement of Changes in Equity
Earnings Per Share (of Tk. 10 /- each) (Adjusted EPS of 2008)
Number of Shares used to compute EPS

4,868,254,915
(2,566,206,626)
2,302,048,289
(1,300,765,878)
(215,192,547)
(1,085,573,331)
1,001,282,411
198,986,379
(289,427,992)
910,840,798
(43,373,371)
867,467,427
(242,727,120)
(173,720,430)
(242,727,120)
624,740,307
33 4.13
151,149,296